In Study 2 , subjects received lenalidomide ( a single 25 mg dose ) alone , the P-gp inhibitor quinidine ( 300-600 mg twice-daily 5 days ) plus lenalidomide ( on Day 4 ) , the P-gp inhibitor/substrate temsirolimus ( a single 25 mg dose ) alone , or lenalidomide plus temsirolimus .